Ebglyss for Atopic Dermatitis One of the latest treatments for atopic dermatitis is Ebglyss (lebrikizumab), a targeted biologic therapy for moderate-to-severe atopic dermatitis. Understanding Atopic Dermatitis Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching, redness, and skin barrier disruption. It affects millions of individuals worldwide and… Read More
Dupilumab (Dupixent) For Prurigo Nodularis
Prurigo nodularis is a challenging problem to treat. It manifests as nodules in the skin, secondary to chronic scratching, and underlying pruritus (itch). Prurigo nodularis has been treated with a wide range of medications and treatments, including topical steroids, antihistamines, mirtazapine, gabapentin, phototherapy, and cyclosporine with variable results. Two recent case study reports indicate that… Read More
Dupilumab for Atopic Dermatitis
Dupilumab (brand name Dupixent) is shaping up to be a game-changer in the treatment of atopic dermatitis, often referred to informally as “eczema”. Dupixent addresses an underlying immune dysregulation that contributes to the development of atopic dermatitis. It blocks IL-4 and IL-13, two important cytokines in the TH2 pathway. In a clinical trial, after 12… Read More
